Replimune Group (NASDAQ:REPL) Given New $22.00 Price Target at Piper Sandler

Replimune Group (NASDAQ:REPL - Free Report) had its price objective raised by Piper Sandler from $14.00 to $22.00 in a research note published on Monday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $19.75.

Replimune Group Trading Up 2.5%

Shares of REPL stock traded up $0.24 during trading hours on Monday, hitting $9.93. 406,743 shares of the company were exchanged, compared to its average volume of 956,796. The firm has a fifty day moving average of $8.34 and a 200 day moving average of $11.05. The firm has a market cap of $765.47 million, a PE ratio of -3.23 and a beta of 0.68. Replimune Group has a 1 year low of $5.66 and a 1 year high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.25) earnings per share. Analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, Director Philip Astley-Sparke sold 32,279 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $260,168.74. Following the completion of the sale, the director now directly owns 1,405,071 shares of the company's stock, valued at approximately $11,324,872.26. This represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. This represents a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock worth $603,655 over the last ninety days. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Replimune Group

Hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC increased its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after acquiring an additional 1,655 shares during the last quarter. Graham Capital Management L.P. boosted its holdings in Replimune Group by 6.1% during the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock valued at $365,000 after acquiring an additional 1,731 shares during the period. Deutsche Bank AG grew its stake in shares of Replimune Group by 0.4% in the first quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock worth $5,496,000 after acquiring an additional 2,140 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock worth $456,000 after acquiring an additional 2,525 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Replimune Group by 19.7% in the first quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock worth $151,000 after acquiring an additional 2,545 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.